Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma

Akifumi Nakamura, Minoru Esaki, Kazuo Nakagawa, Keisuke Asakura, Yoji Kishi, Satoshi Nara, Kazuaki Shimada, Shun ichi Watanabe

Research output: Contribution to journalArticle

Abstract

Objective: The outcomes of surgically treating pulmonary metastases from hepatocellular carcinoma remain unclear. Therefore, we aimed to evaluate patients with hepatocellular carcinoma who underwent pulmonary metastasectomy to assess their survival outcome and prognostic factors. Methods: This retrospective single-center study included 30 patients who underwent pulmonary metastasectomy for hepatocellular carcinoma between January 1980 and December 2016 at the National Cancer Center Hospital. Results: The 1-, 3-, and 5-year overall survival rates after pulmonary metastasectomy were 86.7%, 46.2%, and 33.6%, respectively (median survival time: 25.0 months). The univariate prognostic factors were viral hepatitis (P = 0.019), number of pulmonary metastases (P = 0.002), and other site recurrence before metastasectomy (P = 0.048). Multivariate analysis using a Cox proportional hazards model revealed viral hepatitis (hazard ratio: 3.611, 95% confidence interval: 1.226–10.64; P = 0.02) and ≥ 2 pulmonary metastases (hazard ratio: 4.031, 95% confidence interval: 1.594–10.19; P = 0.003) to be independent prognostic factors. Subgroup analyses of the three risk factors (viral hepatitis, number of pulmonary metastases, and other site recurrence before metastasectomy) revealed that the median survival times after pulmonary metastasectomy were 66.0 and 15.5 months for patients with 0–1 risk factors and those with 2–3 risk factors, respectively (P < 0.001). Conclusions: For patients who underwent pulmonary metastasectomy for hepatocellular carcinoma, median survival time was 25.0 months and decreased with three risk factors which included viral hepatitis, multiple number of pulmonary metastases, and the presence of other site recurrence before metastasectomy.

Original languageEnglish
JournalGeneral thoracic and cardiovascular surgery
DOIs
Publication statusPublished - 2019 Jan 1
Externally publishedYes

Fingerprint

Metastasectomy
Hepatocellular Carcinoma
Lung
Hepatitis
Neoplasm Metastasis
Survival
Recurrence
Confidence Intervals
Cancer Care Facilities
Proportional Hazards Models
Multivariate Analysis
Survival Rate

Keywords

  • Hepatocellular carcinoma
  • Prognostic factors
  • Pulmonary metastasectomy
  • Survival outcome

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma. / Nakamura, Akifumi; Esaki, Minoru; Nakagawa, Kazuo; Asakura, Keisuke; Kishi, Yoji; Nara, Satoshi; Shimada, Kazuaki; Watanabe, Shun ichi.

In: General thoracic and cardiovascular surgery, 01.01.2019.

Research output: Contribution to journalArticle

Nakamura, Akifumi ; Esaki, Minoru ; Nakagawa, Kazuo ; Asakura, Keisuke ; Kishi, Yoji ; Nara, Satoshi ; Shimada, Kazuaki ; Watanabe, Shun ichi. / Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma. In: General thoracic and cardiovascular surgery. 2019.
@article{14b46ee3a18345c895067072a6f392c9,
title = "Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma",
abstract = "Objective: The outcomes of surgically treating pulmonary metastases from hepatocellular carcinoma remain unclear. Therefore, we aimed to evaluate patients with hepatocellular carcinoma who underwent pulmonary metastasectomy to assess their survival outcome and prognostic factors. Methods: This retrospective single-center study included 30 patients who underwent pulmonary metastasectomy for hepatocellular carcinoma between January 1980 and December 2016 at the National Cancer Center Hospital. Results: The 1-, 3-, and 5-year overall survival rates after pulmonary metastasectomy were 86.7{\%}, 46.2{\%}, and 33.6{\%}, respectively (median survival time: 25.0 months). The univariate prognostic factors were viral hepatitis (P = 0.019), number of pulmonary metastases (P = 0.002), and other site recurrence before metastasectomy (P = 0.048). Multivariate analysis using a Cox proportional hazards model revealed viral hepatitis (hazard ratio: 3.611, 95{\%} confidence interval: 1.226–10.64; P = 0.02) and ≥ 2 pulmonary metastases (hazard ratio: 4.031, 95{\%} confidence interval: 1.594–10.19; P = 0.003) to be independent prognostic factors. Subgroup analyses of the three risk factors (viral hepatitis, number of pulmonary metastases, and other site recurrence before metastasectomy) revealed that the median survival times after pulmonary metastasectomy were 66.0 and 15.5 months for patients with 0–1 risk factors and those with 2–3 risk factors, respectively (P < 0.001). Conclusions: For patients who underwent pulmonary metastasectomy for hepatocellular carcinoma, median survival time was 25.0 months and decreased with three risk factors which included viral hepatitis, multiple number of pulmonary metastases, and the presence of other site recurrence before metastasectomy.",
keywords = "Hepatocellular carcinoma, Prognostic factors, Pulmonary metastasectomy, Survival outcome",
author = "Akifumi Nakamura and Minoru Esaki and Kazuo Nakagawa and Keisuke Asakura and Yoji Kishi and Satoshi Nara and Kazuaki Shimada and Watanabe, {Shun ichi}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11748-019-01082-x",
language = "English",
journal = "General Thoracic and Cardiovascular Surgery",
issn = "1863-6705",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Three risk factors for pulmonary metastasectomy in patients with hepatocellular carcinoma

AU - Nakamura, Akifumi

AU - Esaki, Minoru

AU - Nakagawa, Kazuo

AU - Asakura, Keisuke

AU - Kishi, Yoji

AU - Nara, Satoshi

AU - Shimada, Kazuaki

AU - Watanabe, Shun ichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: The outcomes of surgically treating pulmonary metastases from hepatocellular carcinoma remain unclear. Therefore, we aimed to evaluate patients with hepatocellular carcinoma who underwent pulmonary metastasectomy to assess their survival outcome and prognostic factors. Methods: This retrospective single-center study included 30 patients who underwent pulmonary metastasectomy for hepatocellular carcinoma between January 1980 and December 2016 at the National Cancer Center Hospital. Results: The 1-, 3-, and 5-year overall survival rates after pulmonary metastasectomy were 86.7%, 46.2%, and 33.6%, respectively (median survival time: 25.0 months). The univariate prognostic factors were viral hepatitis (P = 0.019), number of pulmonary metastases (P = 0.002), and other site recurrence before metastasectomy (P = 0.048). Multivariate analysis using a Cox proportional hazards model revealed viral hepatitis (hazard ratio: 3.611, 95% confidence interval: 1.226–10.64; P = 0.02) and ≥ 2 pulmonary metastases (hazard ratio: 4.031, 95% confidence interval: 1.594–10.19; P = 0.003) to be independent prognostic factors. Subgroup analyses of the three risk factors (viral hepatitis, number of pulmonary metastases, and other site recurrence before metastasectomy) revealed that the median survival times after pulmonary metastasectomy were 66.0 and 15.5 months for patients with 0–1 risk factors and those with 2–3 risk factors, respectively (P < 0.001). Conclusions: For patients who underwent pulmonary metastasectomy for hepatocellular carcinoma, median survival time was 25.0 months and decreased with three risk factors which included viral hepatitis, multiple number of pulmonary metastases, and the presence of other site recurrence before metastasectomy.

AB - Objective: The outcomes of surgically treating pulmonary metastases from hepatocellular carcinoma remain unclear. Therefore, we aimed to evaluate patients with hepatocellular carcinoma who underwent pulmonary metastasectomy to assess their survival outcome and prognostic factors. Methods: This retrospective single-center study included 30 patients who underwent pulmonary metastasectomy for hepatocellular carcinoma between January 1980 and December 2016 at the National Cancer Center Hospital. Results: The 1-, 3-, and 5-year overall survival rates after pulmonary metastasectomy were 86.7%, 46.2%, and 33.6%, respectively (median survival time: 25.0 months). The univariate prognostic factors were viral hepatitis (P = 0.019), number of pulmonary metastases (P = 0.002), and other site recurrence before metastasectomy (P = 0.048). Multivariate analysis using a Cox proportional hazards model revealed viral hepatitis (hazard ratio: 3.611, 95% confidence interval: 1.226–10.64; P = 0.02) and ≥ 2 pulmonary metastases (hazard ratio: 4.031, 95% confidence interval: 1.594–10.19; P = 0.003) to be independent prognostic factors. Subgroup analyses of the three risk factors (viral hepatitis, number of pulmonary metastases, and other site recurrence before metastasectomy) revealed that the median survival times after pulmonary metastasectomy were 66.0 and 15.5 months for patients with 0–1 risk factors and those with 2–3 risk factors, respectively (P < 0.001). Conclusions: For patients who underwent pulmonary metastasectomy for hepatocellular carcinoma, median survival time was 25.0 months and decreased with three risk factors which included viral hepatitis, multiple number of pulmonary metastases, and the presence of other site recurrence before metastasectomy.

KW - Hepatocellular carcinoma

KW - Prognostic factors

KW - Pulmonary metastasectomy

KW - Survival outcome

UR - http://www.scopus.com/inward/record.url?scp=85062610569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062610569&partnerID=8YFLogxK

U2 - 10.1007/s11748-019-01082-x

DO - 10.1007/s11748-019-01082-x

M3 - Article

C2 - 30820914

AN - SCOPUS:85062610569

JO - General Thoracic and Cardiovascular Surgery

JF - General Thoracic and Cardiovascular Surgery

SN - 1863-6705

ER -